The effects of chronic administration of epidermal growth factor (EGF) to rats on the levels of endogenous EGF in the submandibular glands and kidneys

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The effects of chronic administration of epidermal growth factor (EGF) to rats on the levels of endogenous EGF in the submandibular glands and kidneys. / Vinter-Jensen, Lars; Jøgensen, P E; Poulsen, Steen Seier; Nexø, Ebba.

I: Regulatory Peptides, Bind 67, Nr. 3, 17.12.1996, s. 179-85.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Vinter-Jensen, L, Jøgensen, PE, Poulsen, SS & Nexø, E 1996, 'The effects of chronic administration of epidermal growth factor (EGF) to rats on the levels of endogenous EGF in the submandibular glands and kidneys', Regulatory Peptides, bind 67, nr. 3, s. 179-85.

APA

Vinter-Jensen, L., Jøgensen, P. E., Poulsen, S. S., & Nexø, E. (1996). The effects of chronic administration of epidermal growth factor (EGF) to rats on the levels of endogenous EGF in the submandibular glands and kidneys. Regulatory Peptides, 67(3), 179-85.

Vancouver

Vinter-Jensen L, Jøgensen PE, Poulsen SS, Nexø E. The effects of chronic administration of epidermal growth factor (EGF) to rats on the levels of endogenous EGF in the submandibular glands and kidneys. Regulatory Peptides. 1996 dec. 17;67(3):179-85.

Author

Vinter-Jensen, Lars ; Jøgensen, P E ; Poulsen, Steen Seier ; Nexø, Ebba. / The effects of chronic administration of epidermal growth factor (EGF) to rats on the levels of endogenous EGF in the submandibular glands and kidneys. I: Regulatory Peptides. 1996 ; Bind 67, Nr. 3. s. 179-85.

Bibtex

@article{a3ad2ffab5104adfb9ee45c298349a42,
title = "The effects of chronic administration of epidermal growth factor (EGF) to rats on the levels of endogenous EGF in the submandibular glands and kidneys",
abstract = "Epidermal growth factor (EGF) is mainly produced in the submandibular glands (SMG) and in the kidneys. It has recently been reported that EGF-related ligands may induce their own biosynthesis (autoinduction) in vitro. In the present paper, we investigated whether chronic systemic treatment with EGF influenced the amount of endogenous EGF in the SMG and kidneys. Eight-week-old female Wistar rats were treated with subcutaneous injections of placebo (n = 16) or human recombinant EGF (150 micrograms/kg per day, n = 8) for 4 weeks. Urine was sampled the last 24 h of the study period. At the time of killing, the SMG and the kidneys were removed. The SMG was larger in the EGF-treated animals, 229.8 +/- 35.5 (mean +/- SD) mg than in the control animals, 181.7 +/- 18.1 mg (P <0.01). The total EGF content was smaller (0.51 +/- 0.15 vs. 1.12 +/- 0.40 nmol EGF/SMG, P <0.001). The kidneys were larger in the EGF-treated animals (1.38 +/- 0.08 vs. 1.28 +/- 0.08 g, P <0.05), but the EGF content and urinary excretions were not changed. In conclusion, chronic systemic treatment with EGF causes growth of the SMG with concomitantly reduced contents of EGF, and growth of the kidneys with unchanged content and excretion of EGF. These findings suggest that EGF may play a part in the regulation of the growth of the SMG and in EGF biosynthesis.",
keywords = "Animals, Creatinine, Epidermal Growth Factor, Female, Humans, Immunohistochemistry, Kidney, Organ Size, Proteinuria, Rats, Rats, Wistar, Recombinant Proteins, Submandibular Gland",
author = "Lars Vinter-Jensen and J{\o}gensen, {P E} and Poulsen, {Steen Seier} and Ebba Nex{\o}",
year = "1996",
month = dec,
day = "17",
language = "English",
volume = "67",
pages = "179--85",
journal = "Regulatory Peptides",
issn = "0167-0115",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - The effects of chronic administration of epidermal growth factor (EGF) to rats on the levels of endogenous EGF in the submandibular glands and kidneys

AU - Vinter-Jensen, Lars

AU - Jøgensen, P E

AU - Poulsen, Steen Seier

AU - Nexø, Ebba

PY - 1996/12/17

Y1 - 1996/12/17

N2 - Epidermal growth factor (EGF) is mainly produced in the submandibular glands (SMG) and in the kidneys. It has recently been reported that EGF-related ligands may induce their own biosynthesis (autoinduction) in vitro. In the present paper, we investigated whether chronic systemic treatment with EGF influenced the amount of endogenous EGF in the SMG and kidneys. Eight-week-old female Wistar rats were treated with subcutaneous injections of placebo (n = 16) or human recombinant EGF (150 micrograms/kg per day, n = 8) for 4 weeks. Urine was sampled the last 24 h of the study period. At the time of killing, the SMG and the kidneys were removed. The SMG was larger in the EGF-treated animals, 229.8 +/- 35.5 (mean +/- SD) mg than in the control animals, 181.7 +/- 18.1 mg (P <0.01). The total EGF content was smaller (0.51 +/- 0.15 vs. 1.12 +/- 0.40 nmol EGF/SMG, P <0.001). The kidneys were larger in the EGF-treated animals (1.38 +/- 0.08 vs. 1.28 +/- 0.08 g, P <0.05), but the EGF content and urinary excretions were not changed. In conclusion, chronic systemic treatment with EGF causes growth of the SMG with concomitantly reduced contents of EGF, and growth of the kidneys with unchanged content and excretion of EGF. These findings suggest that EGF may play a part in the regulation of the growth of the SMG and in EGF biosynthesis.

AB - Epidermal growth factor (EGF) is mainly produced in the submandibular glands (SMG) and in the kidneys. It has recently been reported that EGF-related ligands may induce their own biosynthesis (autoinduction) in vitro. In the present paper, we investigated whether chronic systemic treatment with EGF influenced the amount of endogenous EGF in the SMG and kidneys. Eight-week-old female Wistar rats were treated with subcutaneous injections of placebo (n = 16) or human recombinant EGF (150 micrograms/kg per day, n = 8) for 4 weeks. Urine was sampled the last 24 h of the study period. At the time of killing, the SMG and the kidneys were removed. The SMG was larger in the EGF-treated animals, 229.8 +/- 35.5 (mean +/- SD) mg than in the control animals, 181.7 +/- 18.1 mg (P <0.01). The total EGF content was smaller (0.51 +/- 0.15 vs. 1.12 +/- 0.40 nmol EGF/SMG, P <0.001). The kidneys were larger in the EGF-treated animals (1.38 +/- 0.08 vs. 1.28 +/- 0.08 g, P <0.05), but the EGF content and urinary excretions were not changed. In conclusion, chronic systemic treatment with EGF causes growth of the SMG with concomitantly reduced contents of EGF, and growth of the kidneys with unchanged content and excretion of EGF. These findings suggest that EGF may play a part in the regulation of the growth of the SMG and in EGF biosynthesis.

KW - Animals

KW - Creatinine

KW - Epidermal Growth Factor

KW - Female

KW - Humans

KW - Immunohistochemistry

KW - Kidney

KW - Organ Size

KW - Proteinuria

KW - Rats

KW - Rats, Wistar

KW - Recombinant Proteins

KW - Submandibular Gland

M3 - Journal article

C2 - 8988518

VL - 67

SP - 179

EP - 185

JO - Regulatory Peptides

JF - Regulatory Peptides

SN - 0167-0115

IS - 3

ER -

ID: 47486811